DexCom, Inc. (DXCM) Current Ratio: 1.88
Is DexCom, Inc.’s current ratio high or low?
DexCom, Inc.'s current ratio of 1.88 is 40% below its 5-year average of 3.15, near the low end of its 5-year range (1.47–5.58).
The current ratio for DexCom, Inc. (DXCM) is 1.88 as of Wednesday, June 10, 2026. It is above its 12-month average by 12.24% (1.67).
DXCM Current Ratio Chart
DXCM Average Current Ratio Chart
DXCM Current vs Average Current Ratio Chart
DXCM Current Ratio Metrics
CURRENT RATIO
1.88
CURRENT RATIO AVG TTM
1.67
CURRENT RATIO AVG 3Y
2.04
CURRENT RATIO AVG 5Y
3.15
CURRENT RATIO AVG 10Y
3.96
CURRENT RATIO AVG 15Y
4.09
CURRENT RATIO AVG 20Y
4.56
CURRENT VS TTM AVG
+12.24%
CURRENT VS 3Y AVG
-8.07%
CURRENT VS 5Y AVG
-40.22%
CURRENT VS 10Y AVG
-52.49%
CURRENT VS 15Y AVG
-54.03%
CURRENT VS 20Y AVG
-58.74%
DXCM Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | — | 1.88 | 1.67 | 2.04 | 3.15 |
| Biogen Inc. (BIIB) | $29.00B | 2.68 | 2.02 | 2.25 | 2.11 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 0.75 | 0.79 | 0.83 | 0.90 |
| Veeva Systems Inc. (VEEV) | $26.73B | 4.89 | 4.70 | 4.39 | 4.08 |
| Centene Corporation (CNC) | $31.94B | 1.68 | 1.40 | 1.24 | 1.19 |
| Zoetis Inc. (ZTS) | $34.20B | 3.03 | 2.39 | 2.63 | 2.90 |
| Waters Corporation (WAT) | $23.83B | 1.73 | 1.92 | 2.08 | 2.07 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 1.14 | 1.08 | 1.10 | 1.13 |
| BioNTech SE (BNTX) | $21.81B | 7.54 | 7.50 | 7.96 | 6.49 |
| Agilent Technologies, Inc. (A) | $37.17B | 1.96 | 2.02 | 2.17 | 2.21 |
Liquidity Analysis
Current Ratio
1.88
Quick Ratio
1.59
DexCom, Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Current Ratio FAQ
- What is the current ratio for DexCom, Inc. (DXCM)?
- The current ratio for DXCM stock is 1.88.
- Is DexCom, Inc.'s current ratio high or low?
- DexCom, Inc.'s current ratio of 1.88 is 40% below its 5-year average of 3.15, near the low end of its 5-year range (1.47–5.58).
- What is the TTM average current ratio for DexCom, Inc. (DXCM)?
- The TTM average current ratio for DXCM stock is 1.67.
- What is the 3Y average current ratio for DexCom, Inc. (DXCM)?
- The 3Y average current ratio for DXCM stock is 2.04.
- What is the 5Y average current ratio for DexCom, Inc. (DXCM)?
- The 5Y average current ratio for DXCM stock is 3.15.
- What is the 10Y average current ratio for DexCom, Inc. (DXCM)?
- The 10Y average current ratio for DXCM stock is 3.96.
- What is the 15Y average current ratio for DexCom, Inc. (DXCM)?
- The 15Y average current ratio for DXCM stock is 4.09.
- What is the 20Y average current ratio for DexCom, Inc. (DXCM)?
- The 20Y average current ratio for DXCM stock is 4.56.
DexCom, Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 1.88 |
| 2024-12-31 | 1.47 |
| 2023-12-31 | 2.84 |
| 2022-12-31 | 1.99 |
| 2021-12-31 | 5.11 |
| 2020-12-31 | 5.58 |
| 2019-12-31 | 5.47 |
| 2018-12-31 | 7.64 |
| 2017-12-31 | 5.36 |
| 2016-12-31 | 2.73 |
| 2015-12-31 | 3.46 |
| 2014-12-31 | 3.59 |
| 2013-12-31 | 2.90 |
| 2012-12-31 | 3.98 |
| 2011-12-31 | 7.08 |
| 2010-12-31 | 4.36 |
| 2009-12-31 | 1.96 |
| 2008-12-31 | 2.14 |
| 2007-12-31 | 7.97 |
| 2006-12-31 | 10.97 |
| 2005-12-31 | 7.21 |
| 2004-12-31 | 17.39 |
| 2003-12-31 | 20.47 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach